HealthSouth Selects Anodyne Therapy as Preferred Infrared Photo Energy Provider
Anodyne Therapy (Tampa, Fla) announces that the company has entered into a 3-year preferred provider agreement with HealthSouth for infrared photo energy therapy products. HealthSouth is one of the leading national providers of outpatient and inpatient rehab services with more than 1,200 facilities nationwide. Anodyne Therapy is the market-leading infrared photo energy device manufacturer.
Anodyne Therapy technology is currently available nationwide at nearly 5,000 outpatient therapy facilities, hospitals, nursing homes, physician offices, and home health agencies as part of a comprehensive program to improve functional outcomes for patients suffering from painful circulatory conditions caused by diabetes and other chronic conditions. Products are also available for convenient home use.
Visit http://www.anodynetherapy.com for more information.
Celltran and XCELLentis Complete Merger Celltran Limited (Sheffield, United Kingdom) and Innogenetics (Gent, Belgium) are pleased to announce that Celltran has successfully completed its merger with XCELLentis, a subsidiary of Innogenetics, an international biopharmaceutical company. Through the transaction, Celltran has acquired the assets of XCELLentis and Innogenetics has received shares and warrants in the capital of Celltran that will ultimately lead to Innogenetics owning a 51% stake in Celltran.
Celltran is a UK biotechnology company specializing in developing autologous cell therapy products and services to heal wounds. Lyphoderm™, which will shortly enter Phase 3 clinical trials, consists of freeze-dried skin cells of allogeneic (donor-derived) origin with enhanced storage, shelf life, and easy application properties. Two additional therapies from XCELLentis are close to obtaining marketing approval.
The combination of an experienced management team together with a portfolio comprising marketed and late development stage products positions Celltran to effectively target the rapidly growing active therapy sector of wound care that is estimated to be worth £4 billion per year worldwide and to seek additional financing to support the company’s growth plans.
Visit http://www.celltran.com for more information.
|
